A. Pelliccia

Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells

A. Anastasi, R. De Santis, V. D’Alessio, 2007, BMC biotechnology.

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab

C. Albertoni, A. Anastasi, L. Aurisicchio, 2014, Oncotarget.

Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein

F. Felici, A. Anastasi, R. De Santis, 2006, BMC Cancer.

EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

N. Tinari, S. Iacobelli, R. Ghasemi, 2013, Translational oncology.

Therapeutic use of avidin is not hampered by antiavidin antibodies in humans.

Giovanni Paganelli, C. Albertoni, A. Anastasi, 2010, Cancer biotherapy & radiopharmaceuticals.

Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.

Giovanni Paganelli, C. Albertoni, A. Anastasi, 2011, Basic & clinical pharmacology & toxicology.

Chemical Linkage to Injected Tissues Is a Distinctive Property of Oxidized Avidin

C. Albertoni, A. Anastasi, R. De Santis, 2011, PloS one.

Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies

Giovanni Paganelli, Paolo Carminati, C. Albertoni, 2005, Clinical Cancer Research.

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRITR)

G. Cassani, C. Albertoni, A. Anastasi, 2003, British Journal of Cancer.